Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled induction study of SHP647 in moderate to severe Crohn's disease
MOH_2018-07-26_002408Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ontamalimab in Crohn's disease (3 arms), sponsored by Takeda. Primary endpoints: Clinical remission at Week 16 and Endoscopic response at Week 16. Planned start May 2018; status: not yet recruiting.
02
Drugs
ontamalimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2018-07-26_002408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-26_002408.